Drug manufacturers are not keeping their promise to the FDA regarding postapproval drug studies, and the pattern has been occurring for years. An annual report by the FDA showed that nearly two thirds of >1200 postapproval drug studies have yet to start.
"The percentage of open commitments, pending, ongoing, delayed, terminated, and submitted [studies] are all in the same ballpark range," said John Jenkins, MD, director of the FDA's Office of New Drugs.
The FDA's hands are tied because a majority of the studies were voluntarily agreed to at the time of FDA approval, and the agency has no authority to force companies to complete the research. Some studies were required in exchange for quicker approval of drugs for life-threatening diseases. In those cases, the FDA can withdraw a drug's approval if a study goes unfinished, but there is no record of the agency's having done so.
The FDA's report found that 65% of 1231 open studies for chemical-based drugs were "pending," meaning that they had not begun but were not considered delayed. A majority of those studies were agreed to years ago before the FDA issued timelineswhich makes it hard to say whether they are behind schedule, according to Dr. Jenkins.Of the open studies, 2% were considered delayed, and 19% were on schedule. Drugmakers had submitted final reports on 14% of the studies.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs